Use of small nucleic acid in preparation of drug for treating feline infectious peritonitis
By designing specific small RNA to bind to FIPV genes to block viral replication, the problem of insufficient effectiveness and safety of existing treatment methods for infectious peritonitis in cats is solved, and effective treatment of infectious peritonitis in cats is achieved.
Patent Information
- Application Number
- PCT/CN2024/094067
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-17
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-21
AI Technical Summary
The existing treatment methods for infectious peritonitis in cats have problems with effectiveness and safety. There is currently no clear drug that can effectively cure the disease, and the treatment cycle is long and the cure rate is low.
Developed a small RNA or RNA or DNA that is complementary or reversely complementary, with a specific core sequence and length, and binds to the FIPV gene to block viral replication, including short hairpin structural RNA and polynucleosides designed and synthesized Acid, used to prepare pharmaceutical compositions for targeted treatment of infectious peritonitis in cats.
Small RNAs can effectively bind FIPV genes, block viral infection and replication, alleviate animal symptoms, and significantly improve the condition in clinical cases, providing a safe and effective treatment plan.
Smart Images

Figure PCTCN2024094067-FTAPPB-I100001 
Figure PCTCN2024094067-FTAPPB-I100002 
Figure PCTCN2024094067-FTAPPB-I100003
Abstract
Description
Application of small nucleic acids in the preparation of drugs for the treatment of feline infectious peritonitis Technical Field
[0001] The present invention relates to the field of biopharmaceuticals, and in particular to the use of small nucleic acids in the preparation of drugs for treating feline infectious peritonitis. Background Art
[0002] Feline infectious peritonitis (FIP), known as a terminal illness in cats with a 100% mortality rate, is characterized by peritonitis and ascites. It is widespread worldwide, occurring in cats of all ages and sexes, with no seasonal pattern. Existing research generally supports the theory of FIP pathogenesis as an internal variation theory, whereby the virus acquires mutations within an individual to become FIPV. FIPV infects feline monocytes and replicates persistently and efficiently there. Infected monocytes produce cytokines, adhesion molecules, and enzymes, leading to the visible vascular and perivascular lesions of FIP.
[0003] FIP is characterized by systemic vasculitis and / or pyogranulomata, with clinical signs depending on the affected organs. Common sites of FIP lesions include the serosa, kidneys, mesenteric lymph nodes, brain, eyes, liver, spleen, and lungs, resulting in clinical signs including ascites, dyspnea, uveitis, ataxia, and seizures. Affected cats may also present with nonspecific manifestations such as persistent fever, lethargy, anorexia, jaundice, scrotal enlargement, and weight loss. Based on symptoms, FIP is categorized into exudative (wet) and nonexudative (dry) forms. Exudative FIP involves inflammation of the serosa and fluid exudates, with a survival period of days to weeks. Nonexudative FIP primarily features perivascular vasculitis, with a survival period of weeks to months. Some cats may present with a combination of wet and dry forms of FIP, with autopsy demonstrating both serosal and vascular lesions. Both forms of FIP are fatal, but exudative FIP is more common, accounting for approximately 60%-70% of cases, and is more progressive than nonexudative FIP.
[0004] The clinical diagnosis of FIP is difficult, but a reliable diagnosis can be made based primarily on clinical symptoms, combined with medical history and laboratory tests. Laboratory abnormalities in blood routine and biochemical tests may include mild to moderate non-regenerative anemia, microcytemia, lymphocytopenia, neutrophilia (with or without a left shift), hyperbilirubinemia, hyperglobulinemia, hypoalbuminemia, and a white-to-globulin ratio less than 0.8. Exudative FIP presents with exudate, which is typically yellow, transparent, or turbid, and viscous. Laboratory analysis of exudate reveals a high protein content (>35 g / L) and a low nucleated cell count (<5000 nucleated cells / μL). Albumin and globulin can be detected in the exudate, and a white-to-globulin ratio less than 0.4 is highly suggestive of FIP. In addition, peritoneal exudate or blood can be inoculated into feline lung cell cultures for virus isolation and identification. Alternatively, neutralization assays, immunofluorescence assays, ELISA, or PCR can be used. Immunohistochemistry is considered the gold standard for FIP detection due to its high positive detection rate, but false-negative results may occur depending on the sample selected. Commercially available kits for detecting FCoV antibodies in serum, exudate, or cerebrospinal fluid are available for FIP diagnosis, but their use is not recommended clinically because positive results are often found in healthy FCoV-infected cats, but negative results may be observed in cats with FIP. Reverse transcription-polymerase chain reaction (RT-PCR) can detect FCoV RNA in various clinical samples, but it must be used with caution and requires comprehensive interpretation based on the cat's medical history and clinical symptoms. Sequencing can also be performed to detect mutated gene loci, but because genetic mutations are not specific to FCoV, RT-PCR alone is not recommended clinically.
[0005] Research on the treatment of FIP is very old. As early as the 1960s, there were reports of cats highly suspected of having FIP being treated with glucocorticoids, penicillin, and streptomycin. Numerous reports have been published on the treatment of FIP, including studies of glucocorticoids, ribavirin, interferon-α, interferon-ω, and tylosin. Current research on the treatment of FIP primarily focuses on immunosuppressants, antivirals, and immunomodulatory drugs. Immunosuppressants, including glucocorticoids, cyclophosphamide, chloramphenicol, and salicylic acid, can suppress the inflammatory response associated with FIP and may prolong survival in affected cats, but there are currently no definitive studies demonstrating their effectiveness. Immunomodulatory drugs are widely used in cats with FIP, with common ones including tylosin, interferon-α, and interferon-ω. Clinically, immunomodulatory drugs are generally not used alone but are used in combination with immunosuppressive drugs.
[0006] Nucleoside analogs are a recent research hotspot. Nucleoside analogs reportedly being used in FIP treatment studies include GC376 and GS-441524. GC376 is a 3C protease inhibitor. Coronaviruses possess 3C protease, a cysteine protease responsible for cleaving and processing most of the viral polyprotein precursors into mature proteins. The protease inhibitor GC376 works by blocking viral protease cleavage, thereby inhibiting viral replication. While published literature confirms the effectiveness of GC-376 in treating experimental FIP, studies have also shown that GC376 treatment cycles are long, with the potential for relapse and a low cure rate. Whether a cat can be cured depends on its own immune system, making it unreliable. GS-441524 is a competitive inhibitor of nucleoside triphosphates. It can be activated by cellular kinases to nucleoside monophosphates and biologically active triphosphate metabolites (NTPs). Viral RNA requires the participation of natural nucleoside triphosphates during replication, and biologically active NTPs can competitively replace viral RNA-dependent RNA polymerase substrates and RNA chain terminators, thereby inhibiting viral replication. However, this drug is still in the development stage, and research on its use in the treatment of FIP is not yet mature.
[0007] Therefore, there is a need in the art to develop an effective and safe drug for treating feline infectious peritonitis.
[0008] Summary of the Invention
[0009] The purpose of the present invention is to provide an effective and safe drug for treating feline infectious peritonitis.
[0010] In the first aspect of the present invention, a small RNA or a complementary or reverse complementary RNA or DNA thereof, or a modified derivative thereof is provided, wherein the small RNA has a core sequence as shown in GCCGGG and the small RNA is 18-30 nucleotides in length.
[0011] The additional condition is that the small RNA sequence is not the sequence shown in SEQ ID NO.54.
[0012] In another preferred embodiment, the small RNA is non-natural.
[0013] In another preferred embodiment, the small RNA is artificially synthesized or recombinantly expressed.
[0014] In another preferred embodiment, the small RNA is single-stranded or double-stranded.
[0015] In another preferred embodiment, the small RNA has a sequence structure shown in the following formula (I) from the 5' end to the 3' end: (P)nR-(Q)m (I);
[0016] in,
[0017] P is selected from a, u, g or c;
[0018] R is the core sequence, and its nucleotide sequence is shown as GCCGGG;
[0019] Q is selected from a, u, g or c;
[0020] Furthermore, (P)n represents n Ps, wherein n is an integer selected from 0-4,
[0021] The (Q)m represents m Qs, wherein m is an integer selected from 9-24.
[0022] In another preferred embodiment, the small RNA is 19-27 nucleotides in length.
[0023] In another preferred embodiment, the n is 0, 1, 2, 3 or 4.
[0024] In another preferred embodiment, m is an integer selected from 12-19.
[0025] In another preferred embodiment, the small RNA is bound to the FIPV gene.
[0026] In another preferred example, the binding energy of the small RNA to the FIPV gene is less than -15.0 kcal / mol, preferably less than -20.0 kcal / mol, and more preferably less than -24.0 kcal / mol.
[0027] In another preferred embodiment, the FIPV gene is selected from the following group: S (spike protein), M, ORF 1a\1b, or a combination thereof.
[0028] In another preferred embodiment, the nucleotide sequence of the small RNA is selected from the sequence shown in any one of SEQ ID NO.1-53.
[0029] In another preferred embodiment, the nucleotide sequence of the small RNA is selected from SEQ ID NO.1, SEQ ID NO.9 or SEQ ID NO.37.
[0030] In another preferred embodiment, the modification of the modified derivative is one or more modification forms selected from the following groups: sugar modification of nucleotides, modification of the connection mode between nucleotides, cholesterol modification, locked nucleotide modification, peptide modification, lipid modification, halogen modification, hydrocarbon modification, and nucleic acid modification.
[0031] In another preferred embodiment, the sugar modification of the nucleotide includes 2-O-methyl sugar modification, 2-O-methoxyethyl sugar modification, 2-O-alkyl sugar modification, 2-fluoro sugar modification, sugar ring modification, locked nucleotide modification; and / or
[0032] The modification of the connection mode between nucleotides includes phosphorothioate modification and phosphoroalkylation modification; and / or
[0033] The nucleic acid modification includes "TT" modification.
[0034] In the second aspect of the present invention, a short hairpin RNA is provided, wherein the short hairpin RNA can be processed into the small RNA as described in the first aspect of the present invention in a host.
[0035] In another preferred embodiment, the short hairpin RNA is in multiple copies.
[0036] In another preferred embodiment, the short hairpin RNA comprises a plurality of small RNAs as described in the first aspect of the present invention, and the plurality of small RNAs as described in the first aspect of the present invention are the same or different.
[0037] In the third aspect of the present invention, a polynucleotide is provided, which can be transcribed by a host to form the small RNA as described in the first aspect of the present invention, or the short hairpin RNA as described in the second aspect of the present invention.
[0038] In another preferred embodiment, the polynucleotide contains the nucleotide sequence shown in SEQ ID NO.55.
[0039] In another preferred embodiment, the polynucleotide has a structure shown in formula (III): Seq forward-X-Seq reverse (III),
[0040] in,
[0041] Seq forward is a nucleotide sequence that can be processed into the small RNA as described in the first aspect of the present invention in the host;
[0042] Seq reverse is a nucleotide sequence that is substantially complementary or completely complementary to Seq forward;
[0043] X is a spacer sequence located between Seq forward and Seq reverse, and the spacer sequence is not complementary to Seq forward and Seq reverse;
[0044] After the structure shown in formula III is transferred into the host cell, it forms a secondary structure shown in formula (IV):
[0045] Among them, Seq forward, Seq reverse and X are defined as above,
[0046] || represents the complementary base pairing relationship formed between Seq forward and Seq reverse.
[0047] In the fourth aspect of the present invention, an expression vector is provided, which contains the small RNA as described in the first aspect of the present invention, or the short hairpin RNA as described in the second aspect of the present invention, or the polynucleotide as described in the third aspect of the present invention.
[0048] In another preferred embodiment, the expression vector includes: a viral vector and a non-viral vector.
[0049] In another preferred embodiment, the expression vector is a plasmid.
[0050] In the fifth aspect of the present invention, a host cell is provided, wherein the host cell contains the expression vector as described in the fourth aspect of the present invention, or the polynucleotide as described in the third aspect of the present invention is integrated into its genome.
[0051] In another preferred embodiment, the host cells include prokaryotic cells and eukaryotic cells.
[0052] In another preferred embodiment, the host cell is selected from the group consisting of Escherichia coli, actinomycetes, yeast, probiotic spore-forming bacteria, Clostridium butyricum, Lactobacillus, Bifidobacterium, actinomycetes, filamentous fungi, or a combination thereof.
[0053] In a sixth aspect of the present invention, a pharmaceutical composition is provided, comprising:
[0054] (a) an active ingredient selected from the group consisting of: the small RNA as described in the first aspect of the present invention, or an RNA or DNA complementary or reverse complementary thereto, or a modified derivative thereof, or the short hairpin RNA as described in the second aspect of the present invention, or the expression vector as described in the fourth aspect of the present invention, or the host cell as described in the fifth aspect of the present invention; and
[0055] (b) a pharmaceutically acceptable carrier.
[0056] In a seventh aspect of the present invention, a veterinary composition is provided, comprising:
[0057] (A) a first active ingredient selected from:
[0058] (A1) the small RNA according to the first aspect of the present invention, or an RNA or DNA complementary or reverse complementary thereto, or a modified derivative thereof, or the short hairpin RNA according to the second aspect of the present invention, or the expression vector according to the fourth aspect of the present invention, or the host cell according to the fifth aspect of the present invention;
[0059] (A2) the small RNA MIR-2911 having a nucleotide sequence as shown in SEQ ID NO. 54, or an RNA or DNA complementary or reverse complementary thereto, or a modified derivative thereof, or a precursor RNA thereof, or a vector or host cell expressing the same; and
[0060] (A3) a combination of A1 and A2 above; and
[0061] (B) a veterinarily acceptable carrier.
[0062] In another preferred embodiment, the veterinary drug composition is in the form of an oral dosage form, an injection, or an external use drug dosage form.
[0063] In another preferred embodiment, the veterinary pharmaceutically acceptable carrier is selected from the group consisting of water, saline, liposomes, lipids, proteins, protein-antibody conjugates, peptides, cellulose, nanogels, nanoparticles, or a combination thereof.
[0064] In another preferred embodiment, the veterinary drug composition is in the form of a liquid dosage form, preferably an injection, more preferably an intravenous injection or an intraperitoneal injection.
[0065] In another preferred embodiment, the veterinary composition further contains a second active ingredient, which is a drug for preventing, treating and / or alleviating feline infectious peritonitis, or a drug for inhibiting FIPV, or a combination thereof, which is different from the first active ingredient.
[0066] In another preferred embodiment, the second active ingredient includes an immunosuppressant, an immunomodulator, a nutritional supplement or a combination thereof.
[0067] In an eighth aspect of the present invention, there is provided an animal feed, comprising:
[0068] (A) a first active ingredient selected from:
[0069] (A1) the small RNA according to the first aspect of the present invention, or an RNA or DNA complementary or reverse complementary thereto, or a modified derivative thereof, or the short hairpin RNA according to the second aspect of the present invention, or the expression vector according to the fourth aspect of the present invention, or the host cell according to the fifth aspect of the present invention;
[0070] (A2) the small RNA MIR-2911 having a nucleotide sequence as shown in SEQ ID NO. 54, or an RNA or DNA complementary or reverse complementary thereto, or a modified derivative thereof, or a precursor RNA thereof, or a vector or host cell expressing the same; and
[0071] (A3) a combination of A1 and A2 above; and
[0072] (B) A feed-acceptable carrier.
[0073] In the ninth aspect of the present invention, there is provided a use of an active ingredient for preparing a preparation or a pharmaceutical composition, wherein the active ingredient is selected from the group consisting of:
[0074] (A1) the small RNA according to the first aspect of the present invention, or an RNA or DNA complementary or reverse complementary thereto, or a modified derivative thereof, or the short hairpin RNA according to the second aspect of the present invention, or the expression vector according to the fourth aspect of the present invention, or the host cell according to the fifth aspect of the present invention;
[0075] (A2) the small RNA MIR-2911 having a nucleotide sequence as shown in SEQ ID NO. 54, or an RNA or DNA complementary or reverse complementary thereto, or a modified derivative thereof, or a precursor RNA thereof, or a vector or host cell expressing the same;
[0076] (A3) a combination of A1 and A2 above;
[0077] The preparation or pharmaceutical composition is used for:
[0078] (i) prevention, treatment and / or relief of feline infectious peritonitis; and / or
[0079] (ii) Inhibition of feline infectious peritonitis virus (FIPV).
[0080] In a tenth aspect of the present invention, there is provided a method for non-therapeutic inhibition of feline infectious peritonitis virus (FIPV) in vitro, comprising the steps of:
[0081] FIPV or cells infected with FIPV are contacted with the small RNA as described in the first aspect of the present invention, or the RNA or DNA complementary or reverse complementary thereto, or their modified derivatives, or the short hairpin RNA as described in the second aspect of the present invention, or the expression vector as described in the fourth aspect of the present invention, or the host cell as described in the fifth aspect of the present invention, or the pharmaceutical composition as described in the sixth aspect of the present invention, or the veterinary composition as described in the seventh aspect of the present invention, thereby inhibiting the FIPV.
[0082] In another preferred embodiment, the cells are from mammals, preferably from cats.
[0083] In another preferred embodiment, the cells are selected from the group consisting of kidney cells, brain astrocytes, skin fibroblasts, muscle fibroblasts, lung fibroblasts, kidney fibroblasts, embryonic fibroblasts, chondrocytes, osteoblasts, skeletal muscle cells, mesenchymal stem cells, aortic endothelial cells, venous endothelial cells, macrophages, lymphoblasts, T lymphoblasts, peripheral blood monocytes, tongue cells, lung cells, and brain cells.
[0084] In an eleventh aspect of the present invention, a method for preventing and / or treating feline infectious peritonitis is provided, comprising the steps of:
[0085] The small RNA as described in the first aspect of the present invention, or the RNA or DNA complementary or reverse complementary thereto, or their modified derivatives, or the short hairpin RNA as described in the second aspect of the present invention, or the expression vector as described in the fourth aspect of the present invention, or the host cell as described in the fifth aspect of the present invention, or the pharmaceutical composition as described in the sixth aspect of the present invention, or the veterinary composition as described in the seventh aspect of the present invention, or the veterinary feed as described in the eighth aspect of the present invention is administered to a subject in need.
[0086] In another preferred embodiment, the subject is a mammal, preferably a cat.
[0087] In a twelfth aspect of the present invention, an active ingredient is provided for preventing, treating and / or alleviating feline infectious peritonitis, wherein the active ingredient is selected from the group consisting of:
[0088] (A1) the small RNA according to the first aspect of the present invention, or an RNA or DNA complementary or reverse complementary thereto, or a modified derivative thereof, or the short hairpin RNA according to the second aspect of the present invention, or the expression vector according to the fourth aspect of the present invention, or the host cell according to the fifth aspect of the present invention;
[0089] (A2) the small RNA MIR-2911 having a nucleotide sequence as shown in SEQ ID NO. 54, or an RNA or DNA complementary or reverse complementary thereto, or a modified derivative thereof, or a precursor RNA thereof, or a vector or host cell expressing the same;
[0090] (A3) A combination of the above-mentioned A1 and A2.
[0091] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features described in detail below (such as in the embodiments) can be combined with each other to form new or preferred technical solutions. Due to space limitations, they will not be listed here one by one. BRIEF DESCRIPTION OF THE DRAWINGS
[0092] The following drawings are used to illustrate specific embodiments of the present invention and are not used to limit the scope of the present invention defined by the claims.
[0093] Figure 1 shows the bioinformatics prediction results of the lowest free energy of binding of some small RNA sequences to FIPV.
[0094] FIG2 shows a standard curve for detecting the expression of small RNAs in vivo.
[0095] FIG3 shows the X-ray image of the case in Example 5 before treatment.
[0096] FIG4 shows the X-ray images of the case in Example 5 after treatment. DETAILED DESCRIPTION
[0097] After extensive and in-depth research, the inventors have developed for the first time a set of small nucleic acids for the treatment of feline infectious peritonitis and pharmaceutical compositions containing them. Screening and validation revealed that a designed RNA sequence containing the core sequence GCCGGG of the present invention can bind to multiple loci of the FIPV gene, directly targeting FIPV in vitro. Furthermore, formulations containing the designed RNA sequence containing the core sequence as the active pharmaceutical ingredient can achieve antiviral effects in vivo. This foundation led to the completion of the present invention.
[0098] the term
[0099] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0100] As used herein, when used in reference to a specific recited value, the term "about" means that the value may vary by no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes all values between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0101] As used herein, the terms "comprising" or "including" may be open, semi-closed, or closed. In other words, the terms also include "consisting essentially of" or "consisting of."
[0102] As used herein, the terms "host," "subject," and "subject in need thereof" refer to any mammal or non-mammal. Mammals include, but are not limited to, cats, other vertebrates such as rodents, humans, non-human primates such as cows, horses, dogs, pigs, sheep, goats, giraffes, deer, camels, sheep, rats, mice, hares, and rabbits.
[0103] Feline infectious peritonitis
[0104] As used herein, the terms "feline infectious peritonitis," "feline infectious peritonitis," and "FIP" all refer to a serious systemic illness in cats caused by infection with feline coronavirus. Feline coronavirus is a very common pathogen, with a seroprevalence of 12-16% in single-cat settings and 24-87% in multi-cat settings. While most infected cats display only mild symptoms, 5-12% develop severe symptoms, which can lead to the fatal systemic disease known as feline infectious peritonitis.
[0105] As used herein, the terms "feline infectious peritonitis virus" and "FIPV" refer to the virus that causes FIP. FIPV belongs to the genus Coronavirus in the family Coronaviridae. Its genome is a non-segmented, single-stranded, negative-sense RNA of 30 kb. The virus can multiply in various cell types in cats and infect suckling mice, rats, and hamsters. It can be transmitted via insect vectors, the fecal-oral route, and vertically.
[0106] RNAi and antiviral infection
[0107] RNAi (RNA interference) is a specific gene silencing phenomenon mediated by double-stranded or single-stranded small RNAs and participated by specific enzymes. Double-stranded small RNAs (siRNAs) and single-stranded small RNAs can specifically bind to target gene mRNA, causing mRNA degradation and / or translation inhibition, thereby blocking gene expression at the transcriptional, post-transcriptional, and translational levels. The RNAi phenomenon was first discovered in 1990 during research on transgenic plants. In 2001, scientists successfully induced RNAi in cultured mammalian cells, suggesting the possibility of using RNAi technology to treat viral infectious diseases. In recent years, with the deepening of RNAi research, it has provided more effective approaches for the treatment of viral diseases.
[0108] siRNA and short hairpin RNA
[0109] siRNAs are double-stranded RNA molecules of approximately 21 to 25 nucleotides (nt). They are formed from endogenous or exogenous long double-stranded RNA precursors and processed by Dicer (an enzyme in the RNAase III family that is specific for double-stranded RNA). They bind to target mRNAs through perfect complementary pairing, triggering their degradation and ultimately silencing the target gene. siRNAs were first discovered by David Baulcombe's team in the UK as part of the post-transcriptional gene silencing (PTGS) phenomenon in plants. In 2001, Thomas Tuschl's team discovered that synthetic siRNAs can complement the coding sequence of a target gene in mammals, inducing the degradation of the corresponding messenger RNA (mRNA), thereby preventing its translation into protein, thus producing RNAi. This discovery led to the use of controllable RNAi in biomedical research and drug development.
[0110] Short hairpin RNA (shRNA) consists of a sense strand and an antisense strand separated by a stem-loop sequence and is commonly used in constructing expression vectors. shRNA is synthesized in the nucleus of transfected / transduced cells and processed into siRNA in the cytoplasm through the same mechanism as miRNA processing.
[0111] The present invention provides a class of small RNAs for inhibiting feline infectious peritonitis virus, which can be siRNAs and can be produced by processing shRNAs.
[0112] microRNAs and their precursors
[0113] MicroRNA (miRNA) is a small, endogenous, non-coding, single-stranded RNA (SNS) of approximately 22 nucleotides in length that has been recently discovered in eukaryotic organisms such as nematodes, fruit flies, plants, and mammals. Its expression is tissue- and time-specific, negatively regulating gene expression at the post-transcriptional level through base pairing with target mRNAs, leading to mRNA degradation or translational inhibition. It is a key regulatory molecule that regulates the expression of other functional genes. Growing evidence indicates that despite its small size, miRNAs play a crucial role in various biological processes by forming either complete or incomplete complementary pairs with their target mRNAs.
[0114] MicroRNA is a type of endogenous non-coding single-stranded RNA molecule that regulates gene transcription and translation in the body. Its 5' seed region sequence (nucleotides 2 to 8) is highly conserved in evolution and is an important element for this type of nucleic acid molecule to regulate gene expression after transcription in the cytoplasm (Bioinformatics. 2014; 30(10): 1377-83). In addition to the classical regulatory role of the seed region, microRNA has many other regulatory mechanisms and functions that have not yet been clearly explained. For example, microRNA-552-3p can not only bind to the target gene P450 enzyme CYP2E1 in the seed sequence and mRNA 3'-UTR to exert classical post-transcriptional inhibition; at the same time, it can also bind to its promoter region in the non-seed sequence to exert non-classical transcriptional inhibition (Biochim Biophys Acta. 2016; 1859(4): 650-62). This indicates that the regulation of microRNA on its target gene may not only be through the sequence of its seed region, but may also depend on the sequence of its non-seed region.
[0115] The present invention provides a class of small RNAs that inhibit feline infectious peritonitis virus, whose structure, function and physiological metabolic pathways are similar to those of microRNAs, and are also referred to as artificial microRNAs or microRNA analogs. As used herein, the "microRNA" refers to a class of RNA molecules that are processed from transcripts that can form miRNA precursors. Mature miRNAs typically have 18-26 nucleotides (nt) (more particularly about 19-23nt), and miRNA molecules with other numbers of nucleotides are not excluded. In a preferred embodiment of the present invention, mature miRNAs have 18-30 nucleotides. MiRNAs can usually be detected by Northern blots.
[0116] MicroRNAs can be isolated from cells. As used herein, "isolated" refers to a substance that has been separated from its original environment (in the case of a naturally occurring substance, the original environment is the natural environment). For example, polynucleotides and polypeptides in their natural state within living cells are not isolated and purified. However, the same polynucleotides or polypeptides are isolated and purified if they are separated from other substances with which they are naturally present.
[0117] MicroRNAs can be processed from precursor miRNAs (pre-miRNAs), which fold into a stable stem-loop (hairpin) structure. The stem-loop structure is typically 50-100 bp in length. The pre-miRNAs fold into a stable stem-loop structure, with the stem portion of the stem-loop structure containing two substantially complementary sequences on either side. The pre-miRNAs can be natural or synthetic.
[0118] Precursor miRNA can be cleaved to generate miRNA, which can be substantially complementary to at least a portion of the sequence of the mRNA encoding the gene. As used herein, "substantially complementary" means that the sequences of nucleotides are sufficiently complementary to interact in a predictable manner, such as forming a secondary structure (such as a stem-loop structure). Typically, two "substantially complementary" nucleotide sequences have at least 70% of their nucleotides complementary to each other; preferably, at least 80% of their nucleotides are complementary; more preferably, at least 90% of their nucleotides are complementary; further preferably, at least 95% of their nucleotides are complementary; such as 98%, 99% or 100%. Generally, two sufficiently complementary molecules can have a maximum of 5 mismatched nucleotides, such as 1, 2, 3, 4, or 5 mismatched nucleotides.
[0119] As used in this application, a "hairpin" structure, also known as a "stem-loop" structure, refers to a nucleotide molecule that can form a secondary structure comprising a double-stranded region (stem), wherein the double-stranded region is formed by two regions of the nucleotide molecule (located on the same molecule), the two regions being arranged on either side of the double-stranded portion; and it also includes at least one "loop" structure, comprising a non-complementary nucleotide molecule, i.e., a single-stranded region. Even if the two regions of the nucleotide molecule are not completely complementary, the double-stranded portion of the nucleotide can remain double-stranded. For example, insertions, deletions, substitutions, etc. may result in a small region being non-complementary or the small region itself forming a stem-loop structure or other form of secondary structure. However, the two regions may still be substantially complementary and interact in a predictable manner to form a double-stranded region of the stem-loop structure. Stem-loop structures are well known to those skilled in the art. Generally, after obtaining a nucleic acid with a nucleotide sequence having a primary structure, those skilled in the art can determine whether the nucleic acid can form a stem-loop structure.
[0120] The small RNA described in the present invention refers to a small RNA having a core sequence as shown in GCCGGG and a length of 18-30 nucleotides.
[0121] In one embodiment, the small RNA of the present invention has a sequence structure shown in the following formula (I) from the 5' end to the 3' end: (P) n -R-(Q) m (I);
[0122] in,
[0123] P is selected from a, u, g or c;
[0124] R is the core sequence, and its nucleotide sequence is shown as GCCGGG;
[0125] Q is selected from a, u, g or c;
[0126] Furthermore, the (P) n represents n P, wherein n is an integer selected from 0-4,
[0127] The (Q)m represents m Qs, wherein m is an integer selected from 9-24.
[0128] In one embodiment of the present invention, the nucleotide sequence of the RNA of the present invention is selected from the sequence shown in any one of SEQ ID NO.1-53.
[0129] The drug of the present invention comprises the designed single-stranded or double-stranded RNA comprising a core sequence, or a DNA that is completely or partially complementary to the single-stranded or double-stranded RNA, a pharmaceutically acceptable carrier, and a pharmaceutically acceptable excipient.
[0130] In the present invention, RNA can also be appropriately modified to improve drug stability or enhance the targeting of the drug to a specific organ. Those skilled in the art can use common methods to modify the small RNA of the present invention, including (but not limited to): methylation, alkyl modification, glycosylation (such as 2-methoxy-glycosyl modification, alkyl-glycosyl modification, sugar ring modification, etc.), nucleic acid modification, peptide modification, lipid modification, halogen modification, nucleic acid modification (such as "TT" modification), etc.
[0131] In one embodiment, the modified small RNA derivative is a monomer or multimer of a compound having a structure represented by formula (II): (X)r-(Y)s (II)
[0132] in,
[0133] Each X is the small RNA described in the first aspect of the present invention;
[0134] Each Y is independently a modifier that promotes the stability of small RNA administration;
[0135] Y is connected to the left, right or middle of X;
[0136] r is a positive integer of 1-100 (preferably 1-20) (preferably r is 1, 2, 3, 4 or 5);
[0137] s is a positive integer of 1-1000 (preferably 1-200);
[0138] Each "-" represents a linker, a chemical bond, or a covalent bond.
[0139] In one embodiment, the linker is a nucleic acid sequence with a length of 1-10 bases.
[0140] In one embodiment, Y includes, but is not limited to, cholesterol, steroids, sterols, alcohols, organic acids, fatty acids, esters, monosaccharides, polysaccharides, amino acids, polypeptides, mononucleotides, and polynucleotides.
[0141] Polynucleotide constructs
[0142] Based on the small RNA sequences provided by the present invention, polynucleotide constructs can be designed that, after introduction, can be processed into small RNAs that can affect the expression of corresponding mRNAs. In other words, the polynucleotide constructs can upregulate the amount of the corresponding small RNA in vivo. Therefore, the present invention provides an isolated polynucleotide (construct) that can be transcribed into short hairpin RNAs by human cells, which can then be cleaved by the cells and expressed as the small RNAs.
[0143] As a preferred embodiment of the present invention, the polynucleotide construct comprises a structure shown in formula (III): Seq 正向 -X-Seq 反向 (III),
[0144] in,
[0145] Seq 正向 is a nucleotide sequence that can be expressed in cells as the small RNA, Seq 反向 For Seq 正向 Substantially complementary nucleotide sequences; or, Seq 反向 is a nucleotide sequence that can be expressed in cells as the small RNA, Seq 正向 For Seq 正向 Substantially complementary nucleotide sequences; X is located at Seq 正向 and Seq 反 向 The spacer sequence between the two sequences is the same as Seq 正向 and Seq 反向 Not complementary;
[0146] After the structure shown in formula III is transferred into cells, it forms a secondary structure shown in formula (IV):
[0147] In Formula III, Seq 正向 、Seq 反向 and X is defined as above;
[0148] || means in Seq 正向 and Seq 反向 The base pairing relationship formed between them.
[0149] Typically, the polynucleotide construct is located on an expression vector. Therefore, the present invention also includes a vector containing the small RNA or the polynucleotide construct. The expression vector typically also contains a promoter, a replication origin, and / or a marker gene. Methods well known to those skilled in the art can be used to construct the expression vector required for the present invention. These methods include in vitro recombinant DNA technology, DNA synthesis technology, in vivo recombination technology, and the like. The expression vector preferably contains one or more selective marker genes to provide phenotypic traits for selecting transformed host cells, such as karatomycin, gentamicin, hygromycin, and ampicillin resistance.
[0150] In the present invention, the expression vector is not particularly limited, including commercially available or conventionally prepared expression vectors. Representative examples include (but are not limited to): pcDNATM6.2-GW / miR, pcDNA3, pMIR-REPORT miRNA, pAdTrack-CMV, pCAMBIA3101+pUC-35S, pCMVp-NEO-BAN, pBI121, pBin438, pCAMBIA1301, pSV2, CMV4 expression vector, pmiR-RB-Report TM , pshOK-basic, mmu-mir 300-399miRNASelect TM , pshRNA-copGFP Lentivector, GV317, GV309, GV253, GV250, GV249, GV234, GV233, GV232, GV201, GV159 or other GV series expression vectors.
[0151] In one embodiment of the present invention, a plasmid, an adeno-associated viral vector (AAV), or a combination thereof may be used.
[0152] In another preferred embodiment, in the expression vector, the promoter operably linked to the polynucleotide encoding the precursor RNA comprises a constitutive promoter or a tissue-specific promoter, preferably a promoter specifically activated in liver tissue. In other words, these promoters are used to drive the expression of the precursor RNA.
[0153] Representative promoters include, but are not limited to, Pcmv promoter, U6, H1, CD43 promoter, CD45 (LCA) promoter, CD68 promoter, Endoglin (CD105) promoter, Fibronectin promoter, Flt-1 (VEGFR-1) promoter, GFAP promoter, GPIIb (IntegrinαIIb) promoter, ICAM-2 (CD102) promoter, MB (Myoglobin) promoter, NphsI (Nephrin) promoter, SPB promoter, SV40 / hAlb promoter, SYN1 promoter, WASP promoter, or a combination thereof.
[0154] Pharmaceutical compositions and methods of administration
[0155] The present invention provides a pharmaceutical composition, comprising:
[0156] (a) an active ingredient selected from the group consisting of the small RNA described in the first aspect of the present invention, or RNA or DNA complementary or reverse complementary thereto, or modified derivatives thereof, or the short hairpin RNA described in the second aspect of the present invention, or the vector described in the fourth aspect of the present invention, or the host cell described in the fifth aspect of the present invention;
[0157] (b) a pharmaceutically or veterinarily acceptable carrier.
[0158] The drug described in the present invention includes the designed single-stranded or double-stranded RNA including the core sequence, or a DNA that is completely or partially complementary to the single-stranded or double-stranded RNA, and a pharmaceutically (or veterinarily) acceptable carrier, and optionally includes a pharmaceutically (or veterinarily) acceptable excipient.
[0159] As used herein, the term "effective amount" or "effective dose" refers to an amount that can produce a function or activity on humans and / or animals and can be accepted by humans and / or animals.
[0160] As used herein, the term "pharmaceutically (or veterinarily) acceptable" refers to a substance that is suitable for use in cats and / or mammals without excessive adverse side effects (such as toxicity, irritation, and allergic reactions), i.e., a substance with a reasonable benefit / risk ratio. The term "pharmaceutically (or veterinarily) acceptable carrier" refers to a carrier for administering a therapeutic agent, including various excipients and diluents.
[0161] The pharmaceutical compositions of the present invention contain a safe and effective amount of the active ingredient of the present invention and a pharmaceutically (or veterinarily) acceptable carrier. Such carriers include (but are not limited to) saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof. Generally, pharmaceutical formulations should be compatible with the mode of administration. The pharmaceutical compositions of the present invention are available in the form of injections, oral preparations (tablets, capsules, oral liquids), transdermal formulations, and sustained-release formulations. For example, they can be prepared using conventional methods using physiological saline or aqueous solutions containing glucose and other adjuvants. The pharmaceutical compositions are preferably manufactured under sterile conditions.
[0162] The effective amount of the active ingredient of the present invention may vary depending on the mode of administration and the severity of the disease to be treated. The selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials). The factors include, but are not limited to: pharmacokinetic parameters of the active ingredient such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated, the patient's weight, the patient's immune status, the route of administration, etc. Generally, when the active ingredient of the present invention is administered at a dose of about 0.00001 mg-50 mg / kg animal body weight (preferably 0.1 mg-15 mg / kg animal body weight) per day, a satisfactory effect can be obtained. For example, depending on the urgency of the treatment condition, several divided doses may be administered daily, or the dose may be reduced proportionally.
[0163] The pharmaceutically (or veterinarily) acceptable carriers of the present invention include, but are not limited to, water, saline, liposomes, lipids, proteins, protein-antibody conjugates, peptides, cellulose, nanogels, nanoparticles, or combinations thereof. The choice of carrier should be compatible with the mode of administration, as is well known to those skilled in the art.
[0164] In the present invention, the expression vector can be directly administered to the subject, or the expression vector can be prepared into a pharmaceutical combination with a pharmaceutically (or veterinarily) acceptable carrier and then administered. The administration includes intravenous injection.
[0165] The main advantages of the present invention include:
[0166] 1) The small RNA of the present invention has a strong binding ability to FIPV, especially to gene S related to FIPV infectivity and systemic toxicity, thereby blocking viral infection and reducing toxicity; and it can bind to genes related to FIPV genome replication function to block viral replication and spread.
[0167] 2) The microRNA of the present invention can inhibit FIPV and alleviate animal symptoms in clinical cases.
[0168] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples, for which specific conditions are not specified, are generally performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are by weight.
[0169] 1. Bioinformatics Prediction
[0170] A gene database query revealed that the FIPV gene is 29.4 kb in size and contains ten reported genes: S (spike protein), nsp 7a, nsp 3b, ORFs 1a / 1b, nsp 3c, nsp 7b, N, M, E, and nsp 3a. Using the RNAhybrid software tool (Version: RNAhybrid 2.2), with a 2-8 nt seed region as the required match, we predicted binding sites for the Populus euphratica-derived peu-MIR2911 with a minimum free energy of less than -15.0 kcal / mol for the FIPV gene. A total of 32 binding sites were identified, distributed across nearly all genes. Of these, 19 had binding energies less than -20.0 kcal / mol. It has 5 binding sites on gene S, which is related to FIPV infectivity and systemic toxicity, of which 3 sites have binding energies less than -20.0 kcal / mol (2808, 3188, 3682), suggesting that MIR2911 can block viral infectivity and replication and reduce toxicity; it is predicted to obtain 19 binding sites on gene ORF 1a\1b related to FIPV genome replication function, of which 11 sites have binding energies less than -20.0 kcal / mol, suggesting that MIR2911 can block viral replication and transmission.
[0171] peu-MIR2911 sequence (5'-3'):
[0172] CGGCCGGGGGACGGGCUGGG(SEQ ID NO.54)
[0173] 2. Sequence Design and Screening
[0174] Using 3-8 nt of peu-MIR2911 as the core sequence, small RNA sequences were designed and screened.
[0175] Core sequence: GCCGGG
[0176] The design rule of the active ingredient small RNA sequence is as follows: a random 0-4 nt can be added to the beginning of the sequence and a random 9-24 nt can be added to the end of the sequence to make the total length 18-30 nt.
[0177] Based on the above rules, a total of 53 RNA sequences were designed and optimized.
[0178] The binding of the screened RNA sequences to the FIPV gene is shown in Table 1. The binding of some RNAs to the sites is shown in Figure 1. The cell testing method is as described in Example 1.
[0179] Table 1 RNA sequences of the present invention
[0180] Example 1 The plasmid expressing SEQ ID NO.1 can significantly inhibit FIPV in vitro
[0181] Feline kidney cells (CRFK) were cultured at a density of 1×10 5 / mL was inoculated into 96-well plates, cultured at 37°C under 5% CO2 for 48 h, and the experiment was started after 3 passages at a ratio of 1:3.
[0182] FIPV-1146 (feline infectious peritonitis virus) was purchased from ATCC. Pre-titered aliquots of the virus were removed from −70°C and thawed to room temperature in a biosafety cabinet.
[0183] The experimental CRFK cells were divided into two groups, one group was negative control, and the other group was added with 0.01MOI feline coronavirus (FIPV) per well. After one day of infection, the cell activity was detected by CCK-8 method to compare the difference in cell activity between uninfected and infected samples.
[0184] Then, cells were incubated with a plasmid (plasmid:Lipo3000 = 1:3, 5 ng plasmid) carrying the DNA sequence expressing SEQ ID NO. 1 (CCGCCGGGATATTGTGTTCGG, SEQ ID NO. 55) as the experimental group. A plasmid carrying a nonsense sequence at the same concentration was incubated with cells as the plasmid control group. Cell viability was measured on days 2 and 3, and the results are shown in the following table:
[0185] Table 2 Effects of the plasmids of the present invention on the activity of FIPV infected cells
[0186] The test results showed that FIPV virus infection (positive control group) significantly reduced the activity of CRFK cells, and compared with the plasmid control drug, treatment with plasmids carrying therapeutic sequences could effectively enhance cell activity.
[0187] Example 2 Expression detection in animals
[0188] In this example, genetic recombination technology was used to prepare engineered Escherichia coli expressing SEQ ID NO. 9, and the product was amplified by fermentation and extracted by lysis. After purification and filling processes, an injection that met veterinary drug standards was obtained.
[0189] Six 6-8 week old nude mice (3 males and 3 females) were injected intravenously with this agent at 0.2 mg / kg, 1 mg / kg, and 5 mg / kg. Blood was collected 2 and 6 hours after injection to prepare plasma. Total plasma RNA was extracted using the Trizol method, and the expression of the small RNA of SEQ ID NO. 9 in the total RNA was detected by PCR. The standard curve is shown in Figure 2. The primers and probes used in the PCR method were commercially available (Applied Biosciences). The pre-dose was calculated based on the average CT value of each group of mice.
[0190] The reverse transcription system and qPCR system are as follows:
[0191] Reverse transcription system (10 μl in total):
[0192] qPCR system (20 μl in total):
[0193] The reaction procedure includes:
[0194] Reverse transcription reaction procedure:
[0195] 65℃5min→4℃2min→4℃+∞→42℃60min→70℃10min→4℃+∞
[0196] qPCR reaction procedure:
[0197] 95℃5min→40 cycles (95℃10s→60℃30s→72℃20s)→95℃15s→60℃60s→95℃30s
[0198] The test results are shown in Table 3. 3 hours after administration, SEQ ID NO. 9 small RNA was highly expressed in the blood of mice, and the high level of expression was maintained for 6 hours. The expression of SEQ ID NO. 9 small RNA in the blood was dose-dependent, and a response was observed at a low dose of 0.2 mg / kg.
[0199] Table 3 In vivo expression of small RNAs of the present invention
[0200] Example 3 Feline Infectious Peripheral Disease Clinical Case 1
[0201] A female Chinese rural cat, 3 months old, weighing 0.9 kg, began vomiting 2 days ago, averaging 3-4 times a day, with yellow, foamy, and viscous vomitus. Her bowel movements were normal, she had no appetite, and was in good spirits. She had received only one vaccination. A routine blood test showed elevated white blood cell and granulocyte counts, indicating inflammation.
[0202] Table 4 Test results before treatment
[0203] The fecal FPV antigen test result showed a strong positive result (FPV>50.00), and combined with the clinical symptoms, feline infectious peritonitis was confirmed.
[0204] The preparation method of the drug was the same as that of Example 2, except that the sequence used was SEQ ID NO. 1. The drug was intravenously injected at 4 mg / kg for 3 consecutive times, followed by a one-day drug withdrawal. The fecal PFV antigen was retested to be 12.08, and the symptoms were significantly improved.
[0205] Example 4 Feline Infectious Peripheral Disease Clinical Case 2
[0206] A female blue cat, weighing 4.4 kg, had experienced increasing abdominal girth over the past month. Initially dismissed as weight gain, the cat recently experienced a decline in mental state, apathy, and a slight decrease in appetite. The cat's abdominal girth was significantly increased, and palpation revealed significant fluctuations. The cat was not in pain, but had significant difficulty breathing, with the abdomen contracting violently with each respiration. Fecal and ascites samples were collected, and PCR testing confirmed positive for FIPV.
[0207] The X-ray image is shown in Figure 3. It can be clearly observed that there is fluid in the abdomen and pleural effusion, which has severely compressed the lungs.
[0208] The drug was prepared using SEQ ID NO. 37 using the same method as in Example 2. The drug was injected intravenously at a dose of 1 mg / kg, once every other day, for a total of four injections. After treatment, the pulmonary effusion was significantly reduced, and the ascites improved. X-ray images are shown in Figure 4.
[0209] All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.
Claims
1. A small RNA or a complementary or reverse complementary RNA or DNA, or a modified derivative thereof, characterized in that: The small RNA has a core sequence as shown in GCCGGG, and the small RNA is 18-30 nucleotides in length; The additional condition is that the sequence of the small RNA is not the sequence shown in SEQ ID NO.
54.
2. The small RNA according to claim 1, characterized in that The small RNA has a sequence structure shown in the following formula (I) from the 5' end to the 3' end: (P) n -R-(Q) m (I); in, P is selected from a, u, g or c; R is the core sequence, and its nucleotide sequence is shown as GCCGGG; Q is selected from a, u, g or c; Furthermore, the (P) n represents n P, where n is an integer selected from 0-4, The (Q)m represents m Qs, wherein m is an integer selected from 9-24.
3. The small RNA according to claim 1, characterized in that The nucleotide sequence of the small RNA is selected from the sequence shown in any one of SEQ ID NO.1-53.
4. The small RNA according to claim 1, characterized in that The nucleotide sequence of the small RNA is selected from SEQ ID NO.1, SEQ ID NO.9 or SEQ ID NO.
37.
5. A short hairpin RNA, characterized in that: The short hairpin RNA can be processed into the small RNA as claimed in claim 1 in the host.
6. A polynucleotide, characterized in that The polynucleotide can be transcribed by the host to form the small RNA as claimed in claim 1 or the short hairpin RNA as claimed in claim 5.
7. An expression vector, characterized in that: The expression vector contains the small RNA according to claim 1, or the short hairpin RNA according to claim 5, or the polynucleotide according to claim 6.
8. A host cell, characterized in that The host cell contains the expression vector as claimed in claim 7, or the polynucleotide as claimed in claim 6 is integrated into its genome.
9. A veterinary drug composition, characterized in that: The veterinary drug composition comprises: (A) a first active ingredient, the active ingredient being selected from: (A1) the small RNA according to claim 1, or the RNA or DNA complementary or reverse complementary thereto, or the modified derivatives thereof, or the short hairpin RNA according to claim 5, or the polynucleotide according to claim 6, or the expression vector according to claim 7, or the host cell according to claim 8; (A2) a small RNA MIR-2911 having a nucleotide sequence as shown in SEQ ID NO.54, or an RNA or DNA complementary or reverse complementary thereto, or a modified derivative thereof, or a precursor RNA thereof, or a vector or host cell expressing the same; and (A3) a combination of A1 and A2 above; and (B) a veterinarily acceptable carrier.
10. The veterinary drug composition according to claim 9, characterized in that The veterinarily acceptable carrier is selected from the group consisting of water, saline, liposomes, lipids, proteins, protein-antibody conjugates, cellulose, nanogels, nanoparticles or a combination thereof.
11. Use of an active ingredient for preparing a preparation or a pharmaceutical composition, characterized in that: The active ingredient is selected from the following group: (A1) the small RNA according to claim 1, or the RNA or DNA complementary or reverse complementary thereto, or the modified derivatives thereof, or the short hairpin RNA according to claim 5, or the polynucleotide according to claim 6, or the expression vector according to claim 7, or the host cell according to claim 8; (A2) the small RNA MIR-2911 having a nucleotide sequence as shown in SEQ ID NO.54, or RNA or DNA complementary or reverse complementary thereto, or a modified derivative thereof, or a precursor RNA thereof, or a vector or host cell expressing the same; (A3) a combination of A1 and A2 above; The preparation or pharmaceutical composition is used for: (i) prevention, treatment and / or relief of feline infectious peritonitis; and / or (ii) Inhibition of feline infectious peritonitis virus (FIPV).
Citation Information
Patent Citations
HBV treatment
CN103370415A
Gene-regulating compositions and methods for improved immunotherapy
CN112040987A
Extraction process for effectively extracting microRNA effective component from honeysuckle
CN115887519A
Agent for preventing or treating feline infectious peritonitis virus (FIPV)
JP2009165357A
Cited By
Application of gold preparation in preparation of medicine for treating cat infectious peritonitis
CN120478399A
